REZILIENT2: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Sponsor

Taiho Oncology, Inc. (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05967689

Collaborator

(none)

160

Enrollment

Location

Arms

27.5

Anticipated Duration (Months)

5.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of zipalertinib in patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations and other mutations.

Condition or Disease	Intervention/Treatment	Phase
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations	Drug: TAS6417	Phase 2

Detailed Description

This study will evaluate the safety and efficacy of zipalertinib in patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations or other uncommon/single or compound EGFRmt.

Patients will be enrolled into 1 of the 4 following cohorts:

Cohort A ("prior ex20ins treatment") will include patients harboring EGFR ex20ins mutations who have progressed on or after initial treatment with standard platinum-based chemotherapy and prior treatment with an ex20 agent for their advanced disease (administered together or separately).
Cohort B ("1st line") will include patients harboring EGFR ex20ins mutations who have not received prior treatment for advanced disease.
Cohort C ("active brain mets") will include patients harboring EGFR ex20ins or other uncommon single and compound mutations and active brain metastases. Patients may or may not have had prior treatment for advanced disease.
Cohort D ("other uncommon EGFRmt") will include patients harboring other, non ex20ins uncommon single or compound EGFRmt who have progressed on or after treatment with standard systemic anticancer therapy.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

160 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

4 Cohorts based on eligibility criteria4 Cohorts based on eligibility criteria

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.

Actual Study Start Date :

Jul 7, 2023

Anticipated Primary Completion Date :

Jun 30, 2025

Anticipated Study Completion Date :

Oct 20, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort A ("prior ex20ins treatment") Cohort A ("prior ex20ins treatment") participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.	Drug: TAS6417 Oral tablets/capsules Other Names: CLN-081 zipalertinib
Experimental: Cohort B ("1st line treatment") Cohort B participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.	Drug: TAS6417 Oral tablets/capsules Other Names: CLN-081 zipalertinib
Experimental: Cohort C ("active brain mets") Cohort C participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.	Drug: TAS6417 Oral tablets/capsules Other Names: CLN-081 zipalertinib
Experimental: Cohort D ("other uncommon EGFRmt"). Cohort D participants will receive zipalertinib orally twice a day (BID) continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first.	Drug: TAS6417 Oral tablets/capsules Other Names: CLN-081 zipalertinib

Outcome Measures

Primary Outcome Measures

All Cohorts: objective response rate (ORR) [Up to approximately 2 years]

Secondary Outcome Measures

All Cohorts: The rate and severity of treatment emergent AEs [Up to approximately 2 years]
All Cohorts: Overall Survival (OS) [Up to approximately 2 years]
Antitumor activity is assessed by response evaluation criteria RECIST 1.1 by measuring
All Cohorts: Disease control rate (DCR) [Up to approximately 2 years]
All Cohorts: Duration of response (DoR) [Up to approximately 2 years]
Progression-free survival (PFS) [Up to approximately 2 years]
Cohort C: Intracranial (i) Overall Response Rate (iORR) [Up to approximately 2 years]
Cohort C: intracranial duration of complete response (iDCR) [Up to approximately 2 years]
Cohort C: intracranial duration of Response (iDoR) [Up to approximately 2 years]
All Cohorts: Pharmacokinetic (PK) parameter [Up to approximately 2 years]
Minimum Plasma Concentration (Cmin)

Other Outcome Measures

Pharmacokinetic (PK) parameter [Up to approximately 2 years]
Minimum Plasma Concentration [Cmin]
Pharmacokinetic (PK) parameter [Up to approximately 2 years]
Maximum Plasma Concentration [Cmax]
Pharmacokinetic (PK) parameter [Up to approximately 2 years]
Area Under Curve [AUC]
EGFR mutation status [Up to approximately 2 years]
Local central tests results

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Written informed consent
≥18 years of age (or meets the country's regulatory definition of legal adult age, whichever is greater
Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:

Cohort A patients:

Documented EGFR ex20ins mutation status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).
Progressed on or after systemic therapy with an agent targeting ex20ins, either alone or in combination with standard platinum-based chemotherapy for the treatment of advanced disease. Patients who discontinued previous treatment due to unacceptable toxicity are eligible.
Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible.

Cohort B patients:

Documented EGFR ex20ins mutation status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).
Not received prior systemic therapy for locally advanced or metastatic disease. Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed >6 months prior to the first dose of study treatment.
Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible.

Cohort C patients:

Documented EGFR ex20ins mutation status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).
Presence of brain metastasis(es), which may be measurable or nonmeasurable by

RANO-BM criteria, characterized as one of the following:

Newly diagnosed and/or progressive brain metastasis (es) not subjected to CNS-directed therapy, OR
Leptomeningeal disease (LMD) confirmed by a positive cerebrospinal fluid cytology, or unequivocal radiographic and/or clinical determination.

Cohort D patients:

Documented other non-ex20ins uncommon single or compound EGFRmt status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US). A list of eligible mutations will be provided in a separate manual.
Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible.

Measurable disease per RECIST 1.1.
Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers (details provided in a laboratory manual). Patients with insufficient tissue may be eligible following discussion with the sponsor.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17. Adequate organ function, as defined by the hematologic, renal and hepatic laboratory values
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female patients are not considered to be of childbearing potential if they are post-menopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose of study drug and for 6 months after the last dose of study treatment.

Exclusion Criteria:

Patient is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged to be scientifically or medically incompatible with this study.
Has received any of the following within the specific time frame specified:
Patient has received Zipalertinib (TAS6417/CLN081) at any time
Thoracic radiotherapy ≤28 days or palliative radiation ≤14 days prior to the first dose of study treatment
Anticancer immunotherapy ≤28 days prior to the first dose of study treatment
Major surgery (excluding placement of vascular access) ≤28 days prior to the first dose of study treatment.
Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment, except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor.
Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or evidence of clinically active interstitial lung disease.
Impaired cardiac function or clinically significant cardiac disease including any of the following:
History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification (Appendix A)
Serious cardiac arrhythmias requiring treatment.
Resting corrected QT interval (QTc) >470 msec using Fridericia's formula (QTcF).
Is unable to swallow tablets/capsules or has any disease or condition that may significantly affect gastrointestinal absorption of zipalertinib (eg, inflammatory bowel disease, malabsorption syndrome, or prior gastric/bowel resection).
History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:
Adequately treated basal or squamous cell carcinoma of the skin
Cancer of the breast or cervix in situ
Patients with previously treated malignancy if all treatment for that malignancy was completed at least 2 years prior to first dose and no evidence of disease
Patients with concurrent malignancy clinically stable and not requiring tumor-directed treatment
Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is not controlled with treatment.
History of COVID-19 infection within 4 weeks prior to enrolment and/or has persistent clinically significant pulmonary symptoms related to prior COVID-19 infection.
Active bleeding disorders.
Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class.
Is pregnant or lactating.